comparemela.com

Latest Breaking News On - Investor relations for citius pharmaceuticals - Page 1 : comparemela.com

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.